Life Science Software 2013: Markets And Opportunities
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biopharm Reports has carried out six studies in the life science field, which examined the use of specialist software and databases relating to the conduct of PCR, DNA sequencing, DNA microarray, flow cytometry, mass spectrometry and disease biomarker studies. These studies, which involved the participation of more than 2200 end-users in 70 countries, were carried out to assist software developers and vendors to identify market opportunities in these fields.Techniques such as PCR, DNA microarray, DNA sequencing, mass spectrometry and flow cytometry have seen significant growth over the last decade and by 2015, markets for these five areas are expected to exceed $50 billion, globally. However, none of these developments would have been possible without parallel developments in computing and software. Together they provide the systems that allow the high volumes of complex information that these technologies generate, to be handled. Scientific and clinical needs have driven the development of a multitude of data handling, software, databases and bioinformatics platforms. But, despite the many products available, end-users are often restricted in what they can do due to software limitations. Markets are also changing, which demand new software solutions.Biopharm Reports has published a new report on the use of software and databases in the life science field. This is the outcome of six global studies involving more than 2,200 end-users in the PCR, DNA microarray, DNA sequencing, mass spectrometry, flow cytometry and disease biomarker fields. These finding provide substantial information on end-user practices and opportunities in these markets. This Report Provides: • Software and Databases: A breakdown of end-user practices in the use of software and databases (including software/database market brands or in-house) in the conduct of PCR, DNA microarray, DNA sequencing, mass spectrometry, flow cytometry and disease biomarker studies.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV